News - Vertex, Victrelis

Filter

Current filters:

VertexVictrelis

Popular Filters

Incivek and Victrelis important advances in HCV, but still unmet needs

20-06-2012

Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market

07-06-2012

One year post launch, Vertex's (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co (NYSE: MRK) and Roche's…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek versus Victrelis in hepatitis C virus treatment: US physician views

10-04-2012

For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Hepatitis C drug market in Mexico expected to double to $104 million in 2015

21-11-2011

The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice

09-10-2011

Three months after the launch of Vertex’ Incivek (telaprevir) and Merck & Co/Roche’s Victrelis…

IncivekMarkets & MarketingMerck & CoPharmaceuticalRocheVertexVictrelis

Launch trends for Incivek and Victrelis in hepatitis C sector

09-08-2011

Results from a survey fielded one month after the launch of Vertex’ (Nasdaq: VRTX) Incivek (telaprevir)…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top